Sharon Bio-Medicine is currently trading at Rs. 47.60, up by 2.20 points or 4.85% from its previous closing of Rs. 45.40 on the BSE.
The scrip opened at Rs. 46.20 and has touched a high and low of Rs. 50.65 and Rs. 45.30 respectively. So far 302519 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 57.95 on 21-Feb-2014 and a 52 week low of Rs. 27.27 on 20-Nov-2013.
Last one week high and low of the scrip stood at Rs. 50.00 and Rs. 43.50 respectively. The current market cap of the company is Rs. 501.45 crore.
The promoters holding in the company stood at 60.20% while Non-Institutions held 39.80% respectively.
Sharon Bio-Medicine’s Active Pharma Ingredient manufacturing Plant at Plot No. L-6, MIDC, Taloja, near Navi Mumbai District Raigad, Maharashtra has been approved by European Directorate for the Quality of Medicines & Healthcare (EDQM) Council of Europe for complying with the certificate of suitability, as well as the implementation of a suitable Quality Management System based on the Good Manufacturing Practice as laid down in the EU Rules governing Medicinal Product in the European Union, the Company operates in accordance with the requirements of the Resolution AP-CSP (07) 1.
Earlier, the company had completed expansion in its three manufacturing facilities. The total investment in expansion has been incurred to the tune nearly Rs 125 crore. In Dehradun Formulation plant, the expanded expenditure has been around Rs 85 crore whereas capacity of the plant has been increased more than double. Similarly, other plants’ capacity had been added between 30-50%.
Sharon Bio-Medicine’s Toxicology Laboratories is an independent cost centre and is approved by Department of Science & Technology, Government of India. Government of India has approved Good Laboratory Certificate to SA-FORD which is valid as per OECD Countries - GLP studies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
